|Dr. Jonathan E. Lim M.D.||Co-Founder, Chairman & CEO||480k||N/A||1972|
|Dr. David M. Chacko M.D.||Chief Financial Officer||455.3k||N/A||1984|
|Dr. Michael D. Varney Ph.D.||Chairman of R&D, Scientific Advisory Board member and Director||26.3k||N/A||1958|
|Dr. Nik Chetwyn Ph.D.||Sr. VP of Operations||N/A||N/A||N/A|
|Mr. Ebun S. Garner J.D., Esq.||Gen. Counsel & Corp. Sec.||N/A||N/A||1972|
|Dr. Lisa Tesvich-Bonora Ph.D.||Chief People Officer||N/A||N/A||N/A|
|Dr. Wei Lin M.D.||Chief Medical Officer||N/A||N/A||1970|
|Mr. Brian L. Baker CPA, M.S., MS, CPA||Sr. VP of Fin.||N/A||N/A||1967|
|Ms. Chandra D. Lovejoy||Sr. VP of Regulatory Affairs||N/A||N/A||1971|
|Dr. Robert Shoemaker Ph.D.||Sr. VP of Research||N/A||N/A||1981|
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Erasca, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.